This is not the most recent version of the article. View current version (26 APR 2017)

Intervention Protocol

You have free access to this content

Selective progesterone receptor modulators (SPRMs) for uterine fibroids

  1. Ally Murji1,*,
  2. Andrew W Horne2,
  3. Lucy Whitaker3,
  4. Mara L Sobel4,
  5. Hilary OD Critchley2

Editorial Group: Cochrane Gynaecology and Fertility Group

Published Online: 16 OCT 2013

Assessed as up-to-date: 11 MAY 2013

DOI: 10.1002/14651858.CD010770


How to Cite

Murji A, Horne AW, Whitaker L, Sobel ML, Critchley HOD. Selective progesterone receptor modulators (SPRMs) for uterine fibroids (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 10. Art. No.: CD010770. DOI: 10.1002/14651858.CD010770.

Author Information

  1. 1

    Mt Sinai Hospital, University of Toronto, General Obstetrics & Gynecology, Toronto, Ontario, Canada

  2. 2

    University of Edinburgh, MRC Centre for Reproductive Health, Edinburgh, UK

  3. 3

    Royal Infirmary of Edinburgh, Simpson Centre for Reproductive Health, Edinburgh, UK

  4. 4

    McMaster University, Obstetrics and Gynecology, Hamilton, Ontario, Canada

*Ally Murji, General Obstetrics & Gynecology, Mt Sinai Hospital, University of Toronto, 700 University Ave - 3rd Floor, Toronto, Ontario, M5G 1Z5, Canada. Ally.murji@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 16 OCT 2013

SEARCH

This is not the most recent version of the article. View current version (26 APR 2017)

References

Additional references

Baird 2003
  • Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. American Journal of Obstetrics and Gynecology 2003;188(1):100-7. [PUBMED: 12548202]
Bouchard 2011
  • Bouchard P, Chabbert-Buffet N, Fauser BC. Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety. Fertility and Sterility 2011;96(5):1175-89. [PUBMED: 21944187]
Brooks 1996
Cardozo 2012
  • Cardozo ER, Clark AD, Banks NK, Henne MB, Stegmann BJ, Segars JH. The estimated annual cost of uterine leiomyomata in the United States. American Journal of Obstetrics and Gynecology 2012;206(3):211.e1-9. [PUBMED: 22244472]
Chwalisz 2005
  • Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocrine Reviews 2005;26(3):423-38. [PUBMED: 15857972]
Donnez 2012
  • Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. The New England Journal of Medicine 2012;366(5):409-20. [PUBMED: 22296075]
Higgins 2011
  • Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
Ishikawa 2010
Ke 2009
  • Ke LQ, Yang K, Li J, Li CM. Danazol for uterine fibroids. Cochrane Database of Systematic Reviews 2011, Issue 9. [DOI: 10.1002/14651858.CD007692.pub2]
Mutter 2008
  • Mutter GL, Bergeron C, Deligdisch L, Ferenczy A, Glant M, Merino M, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Modern Pathology 2008;21(5):591-8. [PUBMED: 18246050]
Rein 1995
Sabry 2012
Sangkomkamhang 2013
  • Sangkomkamhang US, Lumbiganon P, Laopaiboon M, Mol BW. Progestogens or progestogen-releasing intrauterine systems for uterine fibroids. Cochrane Database of Systematic Reviews (Online) 2013;2:CD008994. [PUBMED: 23450594]
Spies 2002
  • Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstetrics and Gynecology 2002;99(2):290-300. [PUBMED: 11814511]
Stovall 2001
Tristan 2012
Van Voorhis 2009
Wallach 2004
Ware 1992
Wilkens 2008
  • Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. The Journal of Clinical Endocrinology and Metabolism 2008;93(12):4664-71. [PUBMED: 18765509]
Williams 2006
  • Williams VS, Jones G, Mauskopf J, Spalding J, DuChane J. Uterine fibroids: a review of health-related quality of life assessment. Journal of Women's Health 2006;15(7):818-29. [PUBMED: 16999637]